Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| UMC Utrecht | OTHER |
| Amsterdam UMC, location VUmc | OTHER |
| Maastro Clinic, The Netherlands | OTHER |
| Radiotherapiegroep |
Not provided
Not provided
Not provided
Not provided
The objective of the UPGRADE-RT trial is to investigate whether de-escalation of elective radiation dose and introduction of an intermediate dose-level in the treatment of head and neck cancer will results in less radiation sequelae and improved quality of life after treatment whilst the recurrence rate in electively irradiated lymph nodes should not be compromised.
The full study protocol can be found here:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| standard dose prescription | Active Comparator |
|
|
| FDG-PET guided gradient dose prescription | Experimental |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| standard dose prescription | Radiation |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Toxicity: normalcy of diet (score of the performance status scale for head and neck cancer patients) | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Safety: recurrence in electively irradiated lymph nodes | A Kaplan-Meier estimate will be calculated | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Acute toxicity (common toxicity criteria v2.0) | up to 3 months | |
| Late toxicity: swallowing function (water swallowing test) | 3, 12 and 24 months | |
| Late toxicity: salivary gland function (stimulated flow rates) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Prof. Dr. J.H.A.M. Kaanders | Radboud University Nijmegen Medical Center | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| VU University Medical Center Amsterdam | Amsterdam | Netherlands | ||||
| Radiotherapiegroep, Arnhem |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40233286 | Result | van den Bosch S, Doornaert PAH, Hoebers FJP, Kreike B, Vergeer MR, Zwijnenburg EM, Cox MC, Hannink G, Dijkema T, Kaanders JHAM; Dutch Head and Neck Society. Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial. J Clin Oncol. 2025 Aug 10;43(23):2583-2594. doi: 10.1200/JCO-24-02194. Epub 2025 Apr 15. | |
| 41057084 |
Not provided
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Not provided
| FDG-PET guided gradient dose prescription | Radiation |
|
|
| 3, 12 and 24 months |
| Late toxicity: thyroid gland function (thyroid stimulating hormone blood test) | 3, 12 and 24 months |
| Quality of life (EORTC QLQ-C30 and QLQ-H&N35 questionnaires) | 3, 6, 12 and 24 months |
| Xerostomia related quality of life (GRIX questionnaire) | 3, 6, 12 and 24 months |
| Dysphagia related quality of life (SWAL-QOL questionnaire) | 3, 6, 12 and 24 months |
| Loco-regional control | A Kaplan-Meier estimate will be calculated | 24 months |
| Overall survival | A Kaplan-Meier estimate will be calculated | 24 months |
| Disease specific survival | A Kaplan-Meier estimate will be calculated | 24 months |
| Arnhem |
| Netherlands |
| MAASTRO clinic, Maastricht | Maastricht | Netherlands |
| Radboud University Nijmegen Medical Center | Nijmegen | Netherlands |
| University Medical Center Utrecht | Utrecht | Netherlands |
| Result |
| van den Bosch S, Cox MC, Doornaert PAH, Hoebers FJP, Kreike B, Vergeer MR, Zwijnenburg EM, Hannink G, Dijkema T, Kaanders JHAM; Dutch Head and Neck Society. Dose de-escalation of elective neck irradiation in head and neck cancer: A secondary analysis of acute toxicity findings from the randomized controlled UPGRADE-RT trial. Radiother Oncol. 2025 Dec;213:111196. doi: 10.1016/j.radonc.2025.111196. Epub 2025 Oct 5. |
| 28327089 | Derived | van den Bosch S, Dijkema T, Kunze-Busch MC, Terhaard CH, Raaijmakers CP, Doornaert PA, Hoebers FJ, Vergeer MR, Kreike B, Wijers OB, Oyen WJ, Kaanders JH. Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma. BMC Cancer. 2017 Mar 21;17(1):208. doi: 10.1186/s12885-017-3195-7. |
| ID | Term |
|---|---|
| D006258 | Head and Neck Neoplasms |
| D002294 | Carcinoma, Squamous Cell |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D018307 | Neoplasms, Squamous Cell |
Not provided
Not provided
| ID | Term |
|---|---|
| D055656 | Prescriptions |
| ID | Term |
|---|---|
| D010593 | Pharmaceutical Services |
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |
Not provided
Not provided